Joseph W Landry
Overview
Explore the profile of Joseph W Landry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
May L, Hu B, Jerajani P, Jagdeesh A, Alhawiti O, Cai L, et al.
Cancer Res
. 2024 Sep;
84(24):4140-4155.
PMID: 39312191
There is a significant sex bias in lung cancer, with males showing increased mortality compared with females. A better mechanistic understanding of these differences could help identify therapeutic targets to...
2.
May L, Shows K, Nana-Sinkam P, Li H, Landry J
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370722
Sex disparities in the incidence and mortality of lung cancer have been observed since cancer statistics have been recorded. Social and economic differences contribute to sex disparities in lung cancer...
3.
Landry J, Das S, Fisher P
Adv Cancer Res
. 2023 Mar;
158:xiii-xvi.
PMID: 36990540
No abstract available.
4.
Lancaster E, Vladimirov V, Riley B, Landry J, Roberson-Nay R, York T
Epigenetics
. 2022 May;
17(12):1753-1773.
PMID: 35608069
Although epigenome-wide association studies (EWAS) have been successful in identifying DNA methylation (DNAm) patterns associated with disease states, any further characterization of etiologic mechanisms underlying disease remains elusive. This knowledge...
5.
Bhoopathi P, Pradhan A, Kumar A, Maji S, Mannangatti P, Deng X, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326649
Progression-elevated gene-3 (PEG-3) and rat growth arrest and DNA damage-inducible gene-34 (GADD34) display significant sequence homology with regulation predominantly transcriptional. The rat full-length (FL) and minimal (min) PEG-3 promoter display...
6.
Zahid H, Buchholz C, Singh M, Ciccone M, Chan A, Nithianantham S, et al.
J Med Chem
. 2021 Sep;
64(18):13902-13917.
PMID: 34515477
The nucleosome remodeling factor (NURF) alters chromatin accessibility through interactions with its largest subunit,the bromodomain PHD finger transcription factor BPTF. BPTF is overexpressed in several cancers and is an emerging...
7.
Pradhan A, Maji S, Bhoopathi P, Talukdar S, Mannangatti P, Guo C, et al.
Proc Natl Acad Sci U S A
. 2021 May;
118(21).
PMID: 34016751
Melanoma differentiation associated gene-9 (MDA-9), Syntenin-1, or syndecan binding protein is a differentially regulated prometastatic gene with elevated expression in advanced stages of melanoma. MDA-9/Syntenin expression positively associates with advanced...
8.
Tyutyunyk-Massey L, Sun Y, Dao N, Ngo H, Dammalapati M, Vaidyanathan A, et al.
Mol Cancer Res
. 2021 Apr;
19(8):1338-1349.
PMID: 33811160
Epigenetic regulators can modulate the effects of cancer therapeutics. To further these observations, we discovered that the bromodomain PHD finger transcription factor subunit (BPTF) of the nucleosome remodeling factor (NURF)...
9.
Yu X, Liu W, Chen S, Cheng X, Paez P, Sun T, et al.
J Immunother Cancer
. 2021 Jan;
9(1).
PMID: 33468554
Background: The efficacy of cancer immunotherapy can be limited by the poor immunogenicity of cancer and the immunosuppressive tumor microenvironment (TME). Immunologically programming the TME and creating an immune-inflamed tumor...
10.
Saleh T, Tyutyunyk-Massey L, Murray G, Alotaibi M, Kawale A, Elsayed Z, et al.
Biochem Pharmacol
. 2018 Dec;
162:202-212.
PMID: 30576620
H460 non-small cell lung, HCT116 colon and 4T1 breast tumor cell lines induced into senescence by exposure to either etoposide or doxorubicin were able to recover proliferative capacity both in...